Key Analysts at Societe Generale Have Maintained their ‘Buy’ rating for Croda International PLC (LON:CRDA) Shares Today. Their PT Provided Is GBX 3300.00

Share

Croda International PLC (LON:CRDA) Rating Reaffirmed

In analysts report disseminated on Wednesday, 2 December, The Buy rating of Croda International PLC (LON:CRDA) shares was kept steady at Societe Generale, who now has a GBX 3300.00 Estimated Target Price on the stock. Societe Generale’s Estimated Target Price could mean a possible upside of 16.40% from the current stock price of the company.

From a total of 18 analysts covering Croda International PLC (LON:CRDA) stock, 6 rate it a ”Buy”, 2 a “Sell”, and 9 a ”Hold”. This means that 35% of the ratings are positive. The highest target price is GBX 3400 while the lowest target price is GBX 1800. The mean of all analyst targets is GBX 2927.06 with a 3.53% above today’s (GBX 2892.89) stock price. Croda International PLC was the topic of 34 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on December 2 with “Neutral” rating. UBS maintained shares with “Sell” rating and GBX 2350 target share price in a report from a November 25. BNP Paribas maintained CRDA stock in a recent report from December 1 with “Neutral” rating. Barclays Capital maintained the rating on November 13. Barclays Capital has a “Equalweight” rating and a GBX 3100 price target on shares. Finally, Investec maintained the stock with “Hold” rating in a report issued on a November 26.

Approximately 1,832 shares of stock traded hands. Croda International Plc (LON:CRDA) has risen 3.12% since May 5, 2015 and is uptrending. It has outperformed by 3.32% the S&P500.

Key Analysts at Societe Generale Have Maintained their ‘Buy’ rating for Croda International PLC (LON:CRDA) Shares Today. Their PT Provided Is GBX 3300.00

Croda International Plc is a United Kingdom specialty chemical manufacturer. The company has a market cap of 3.93 billion GBP. The Company’s divisions include Personal Care, Life Sciences, Performance Technologies and Industrial Chemicals. It has 22.48 P/E ratio. The Firm is a supplier of specialty ingredients for the personal care industry.

COMMENTS: